Zentalis Pharmaceuticals Inc. Common Stock (ZNTL)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of businesses that consume capital without producing profits, and Zentalis fits that description. It is a clinical-stage biotechnology company with 106 employees, focused on azenosertib for ovarian cancer and other tumors. The science may be promising, but the financial record is not. In fiscal 2025, the year ended 2025-12-31, it reported no revenue and a net loss of $137.1 million, or diluted EPS of -$1.91. In fiscal 2024, the year ended 2024-12-31, revenue was $67.4 million with a net loss of $165.8 million. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $42.3 million, or EPS of -$0.59, worse than the $26.9 million net loss in fiscal Q2 2025. Trailing free cash flow was negative $128.1 million, a FairStock calculation, a -74.5% FCF yield on the $172 million market cap. Debt-to-equity is 0.26, not extreme, but Altman Z-score is -6.59 and Piotroski F-score is 1/9, both FairStock calculations. At the 2026-10-13 close of $2.40, P/B is 1.20, but book value in a loss-making biotech is not a reliable moat. The company has no durable competitive advantage I can identify, no profits, and negative returns; ROE is -66.75% and ROCE is -33.15%, FairStock calculations. The FairStock score is 58/100, and the Lynch category is none because it has lost money in each of the last four years. This is a speculative pipeline bet, not a Graham-style bargain.

In plain English: Zentalis Pharmaceuticals is a clinical-stage biotech company trying to develop a cancer drug called azenosertib, mainly for ovarian cancer and other tumors. The company is not profitable, has been spending more cash than it brings in, and reported net losses in recent years. At $2.40 a share, the price is low compared with what the books say the company owns, but without profits or positive cash flow it is hard to call the stock clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer